Sutro Biopharma, Inc. (STRO) stock
STRONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$9.59−0.67 (-6.53%)
Close on Nov 12, 2026Market cap $159.01MP/E –Yield –
Sutro Biopharma revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Sutro Biopharma's revenue for the twelve months ending Sep 30, 2026 was $45.11M, down 57.3% year over year. For fiscal 2025 it was $102.48M, up 65.2% from the year before. The highest annual figure on record is $153.73M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $102.48M | +65.2% |
| FY2024 | Dec 31, 2024 | $62.04M | -59.6% |
| FY2023 | Dec 31, 2023 | $153.73M | +126.8% |
| FY2022 | Dec 31, 2022 | $67.77M | +9.5% |
| FY2021 | Dec 31, 2021 | $61.88M | +44.8% |
| FY2020 | Dec 31, 2020 | $42.72M | -0.0% |
| FY2019 | Dec 31, 2019 | $42.74M | +11.2% |
| FY2018 | Dec 31, 2018 | $38.42M | -25.7% |
| FY2017 | Dec 31, 2017 | $51.74M | -13.4% |
| FY2016 | Dec 31, 2016 | $59.73M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $9.10M | -6.1% |
| Q2 FY2026 | Jun 30, 2026 | $9.84M | -84.6% |
| Q1 FY2026 | Mar 31, 2026 | $14.52M | -16.5% |
| Q4 FY2025 | Dec 31, 2025 | $11.65M | -21.4% |
| Q3 FY2025 | Sep 30, 2025 | $9.69M | +13.8% |
| Q2 FY2025 | Jun 30, 2025 | $63.75M | +148.0% |
| Q1 FY2025 | Mar 31, 2025 | $17.40M | +33.8% |
| Q4 FY2024 | Dec 31, 2024 | $14.81M | -87.0% |
| Q3 FY2024 | Sep 30, 2024 | $8.52M | -49.7% |
| Q2 FY2024 | Jun 30, 2024 | $25.71M | +146.9% |
| Q1 FY2024 | Mar 31, 2024 | $13.01M | +2.6% |
| Q4 FY2023 | Dec 31, 2023 | $113.72M | +1217.4% |
| Q3 FY2023 | Sep 30, 2023 | $16.92M | -32.7% |
| Q2 FY2023 | Jun 30, 2023 | $10.41M | -62.9% |
| Q1 FY2023 | Mar 31, 2023 | $12.67M | +114.9% |
| Q4 FY2022 | Dec 31, 2022 | $8.63M | -19.0% |
| Q3 FY2022 | Sep 30, 2022 | $25.15M | +195.3% |
| Q2 FY2022 | Jun 30, 2022 | $28.10M | +0.2% |
| Q1 FY2022 | Mar 31, 2022 | $5.90M | -59.8% |
| Q4 FY2021 | Dec 31, 2021 | $10.65M | +28.7% |
| Q3 FY2021 | Sep 30, 2021 | $8.52M | -52.2% |
| Q2 FY2021 | Jun 30, 2021 | $28.05M | +196.2% |
| Q1 FY2021 | Mar 31, 2021 | $14.66M | +105.0% |
| Q4 FY2020 | Dec 31, 2020 | $8.28M | -26.8% |
| Q3 FY2020 | Sep 30, 2020 | $17.82M | +45.2% |
| Q2 FY2020 | Jun 30, 2020 | $9.47M | -10.0% |
| Q1 FY2020 | Mar 31, 2020 | $7.15M | -17.1% |
| Q4 FY2019 | Dec 31, 2019 | $11.31M | -40.8% |
| Q3 FY2019 | Sep 30, 2019 | $12.28M | +56.7% |
| Q2 FY2019 | Jun 30, 2019 | $10.53M | +84.5% |
| Q1 FY2019 | Mar 31, 2019 | $8.63M | +49.0% |
| Q4 FY2018 | Dec 31, 2018 | $19.09M | +372.4% |
| Q3 FY2018 | Sep 30, 2018 | $7.84M | -55.2% |
| Q2 FY2018 | Jun 30, 2018 | $5.70M | -62.9% |
| Q1 FY2018 | Mar 31, 2018 | $5.79M | -61.0% |
| Q4 FY2017 | Dec 31, 2017 | $4.04M | – |
| Q3 FY2017 | Sep 30, 2017 | $17.50M | – |
| Q2 FY2017 | Jun 30, 2017 | $15.36M | – |
| Q1 FY2017 | Mar 31, 2017 | $14.85M | – |
See a number that looks wrong?